share_log

Peijia Medical Limited's (HKG:9996) 26% Share Price Surge Not Quite Adding Up

Peijia Medical Limited's (HKG:9996) 26% Share Price Surge Not Quite Adding Up

沛嘉醫療(臨時代碼)(HKG:9996)股價暴漲26%,但並沒有完全解釋清楚
Simply Wall St ·  08/29 18:24

Peijia Medical Limited (HKG:9996) shares have had a really impressive month, gaining 26% after a shaky period beforehand. Still, the 30-day jump doesn't change the fact that longer term shareholders have seen their stock decimated by the 61% share price drop in the last twelve months.

Since its price has surged higher, when almost half of the companies in Hong Kong's Medical Equipment industry have price-to-sales ratios (or "P/S") below 2.6x, you may consider Peijia Medical as a stock probably not worth researching with its 3.4x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.

1724970242476
SEHK:9996 Price to Sales Ratio vs Industry August 29th 2024

How Has Peijia Medical Performed Recently?

Peijia Medical certainly has been doing a good job lately as it's been growing revenue more than most other companies. It seems the market expects this form will continue into the future, hence the elevated P/S ratio. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

Want the full picture on analyst estimates for the company? Then our free report on Peijia Medical will help you uncover what's on the horizon.

How Is Peijia Medical's Revenue Growth Trending?

In order to justify its P/S ratio, Peijia Medical would need to produce impressive growth in excess of the industry.

Retrospectively, the last year delivered an exceptional 45% gain to the company's top line. This great performance means it was also able to deliver immense revenue growth over the last three years. So we can start by confirming that the company has done a tremendous job of growing revenue over that time.

Looking ahead now, revenue is anticipated to climb by 41% per year during the coming three years according to the four analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 42% per year, which is not materially different.

With this in consideration, we find it intriguing that Peijia Medical's P/S is higher than its industry peers. Apparently many investors in the company are more bullish than analysts indicate and aren't willing to let go of their stock right now. These shareholders may be setting themselves up for disappointment if the P/S falls to levels more in line with the growth outlook.

What Does Peijia Medical's P/S Mean For Investors?

Peijia Medical's P/S is on the rise since its shares have risen strongly. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Seeing as its revenues are forecast to grow in line with the wider industry, it would appear that Peijia Medical currently trades on a higher than expected P/S. Right now we are uncomfortable with the relatively high share price as the predicted future revenues aren't likely to support such positive sentiment for long. This places shareholders' investments at risk and potential investors in danger of paying an unnecessary premium.

And what about other risks? Every company has them, and we've spotted 2 warning signs for Peijia Medical you should know about.

If you're unsure about the strength of Peijia Medical's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論